Risk adjusted net present value: What is the current valuation of Pharma Mar’s Ecubectedin?
Pharmaceutical Technology
JUNE 6, 2023
Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. According to Globaldata, it is involved in 5 clinical trials, which are ongoing. It also develops RNAi candidates for the treatment of retina diseases. Buy the model here. over FY2021. in FY2021.
100 
Let's personalize your content